Advertisement

Topics

Bristol-Myers and Five Prime Present Early-Stage Data of Cabiralizumab and Opdivo in Solid Tumors

13:44 EST 9 Nov 2017 | Speciality Pharma Journal

PRINCETON, N.J. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (NASDAQ:FPRX) today announced preliminary results from a dose escalation and expansion study evaluating the safety, pharmacokinetics and pharmacodynamics of cabiralizumab in combination with Opdivo (nivolumab) in patients with advanced solid tumors. This is the first disclosure of a clinical experience evaluating an anti-CSF-1 receptor …

Original Article: Bristol-Myers and Five Prime Present Early-Stage Data of Cabiralizumab and Opdivo in Solid Tumors

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers and Five Prime Present Early-Stage Data of Cabiralizumab and Opdivo in Solid Tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...